All In Biotech

Drug Trial Radar · NCT06962839

A Study to Test Whether BI 1815368 Helps People With an Eye Condition Called Diabetic Macular Edema

A Randomised, Double-masked, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Oral BI 1815368 in Participants With Centre-involved Diabetic Macular Edema for 48 Weeks of Treatment (THULITE)

Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 300 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

300

Planned (sponsor's estimate)

Start

Jun 5, 2025

Primary completion

Mar 1, 2028

Study completion Mar 29, 2028

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
May 8, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is open to adults 18 and older with an eye condition called diabetic macular edema. People are required to have a specific type of diabetic macular edema called centre-involved diabetic macular edema (CI-DME) to take part. The purpose of this study is to find out whether a medicine called BI 1815368 improves sight in people with CI-DME and to find the most suitable dose. This study has 2 parts. In the first part, participants are put into 2 groups of equal size randomly, which means by chance. One group takes BI 1815368 tablets and the other group takes placebo tablets. Placebo tablets look like BI 1815368 tablets but do not contain any medicine. In the second part, participants are put into 4 groups of equal size randomly. 3 groups take different daily doses of the study medicine, BI 1815368, while 1 group takes placebo. All participants take tablets twice a day for about 11 months. Participants are in the study for about 1 year. During this time, they visit the study site at least 16 times. Participants taking metformin have 3 additional study visits. At visits, doctors check the participant's vision and collect information on any health problems. They take detailed pictures of the eye. The changes over time are compared between the groups to see if the treatment works.

Conditions

  • Macular Edema

Interventions

  • BI 1815368Drug

    BI 1815368

  • PlaceboDrug

    Placebo matching BI 1815368

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Occurrence (yes/no) of a gain of ≥10 Early Treatment Diabetic Retinopathy Study (ETDRS) letters compared with baseline in the study eye at Week 48Time frame: at baseline, at week 48

Locations

98 sites in 9 countries. Site status is shown where the registry gives one.

  • Arizona Retina & Vitreous Research, Central Phoenix

    Phoenix, Arizona · Recruiting

  • Win Retina

    Arcadia, California · Recruiting

  • Retina Associates of Southern California

    Huntington Beach, California · Recruiting

  • Retinal Consultants Medical Group, Inc

    Modesto, California · Recruiting

  • Eye Research Foundation

    Newport Beach, California · Recruiting

  • Doheny Eye Center UCLA Arcadia

    Pasadena, California · Recruiting

  • Retina Consultants of San Diego

    Poway, California · Recruiting

  • West Coast Retina Medical Group, Inc.

    San Francisco, California · Recruiting

  • Colorado Retina Associates

    Lakewood, Colorado · Recruiting

  • Connecticut Eye Consultants, PC

    Danbury, Connecticut · Not yet recruiting

  • Retina Group of Florida - Fort Lauderdale Retina Center

    Fort Lauderdale, Florida · Not yet recruiting

  • Florida Retina Institute, Jacksonville Southside

    Jacksonville, Florida · Not yet recruiting

  • Advanced Research Institute

    Pompano Beach, Florida · Recruiting

  • East Florida Eye Institute

    Stuart, Florida · Not yet recruiting

  • Center for Retina and Macular Disease

    Winter Haven, Florida · Recruiting

  • Southeast Retina Center, PC

    Augusta, Georgia · Not yet recruiting

  • Associated Vitreoretinal and Uveitis Consultants

    Carmel, Indiana · Recruiting

  • University of Kansas Medical Center

    Kansas City, Kansas · Recruiting

  • Cumberland Valley Retina Consultants

    Hagerstown, Maryland · Recruiting

  • Deep Blue Retina Clinical Research PLLC

    Southaven, Mississippi · Not yet recruiting

  • Sierra Eye Associates

    Reno, Nevada · Recruiting

  • North Carolina Retina Associates

    Wake Forest, North Carolina · Recruiting

  • Cleveland Clinic

    Cleveland, Ohio · Recruiting

  • Verum Research, LLC

    Eugene, Oregon · Recruiting

  • Retina Consultants of Carolina, P.A.

    Greenville, South Carolina · Recruiting

  • Tennessee Retina

    Nashville, Tennessee · Recruiting

  • Austin Research Center for Retina, PLLC

    Austin, Texas · Recruiting

  • Austin Retina Associates

    Austin, Texas · Recruiting

  • Austin Clinical Research, LLC

    Austin, Texas · Recruiting

  • Retina Consultants of Texas - Beaumont

    Beaumont, Texas · Not yet recruiting

  • Texas Retina Associates

    Dallas, Texas · Recruiting

  • Star Retina

    Fort Worth, Texas · Not yet recruiting

  • Medical Center Ophthalmology Associates

    San Antonio, Texas · Not yet recruiting

  • Retinal Consultants of San Antonio

    San Antonio, Texas · Not yet recruiting

  • Retina Center Of Texas

    Southlake, Texas · Recruiting

  • Retina Consultants of Texas

    The Woodlands, Texas · Recruiting

  • Piedmont Eye Center

    Lynchburg, Virginia · Recruiting

  • Retina Consultants, PLLC

    Charleston, West Virginia · Not yet recruiting

  • West China Hospital, Sichuan University

    Chengdu, China · Recruiting

  • Shanghai General Hospital

    Shanghai, China · Recruiting

Showing 40 of 98 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.